Clinicians prescribing immune checkpoint inhibitor (ICI) therapy, used in several cancer typess, should be vigilant of treatment-related neurotoxicities, as early diagnosis and treatment can help prevent morbidity and mortality.
Why this matters
ICI-associated neurotoxicities are uncommon and can involve the CNS, peripheral nervous and neuroendocrine systems. If untreated, these neurotoxicities can be associated with significant morbidity and mortality.
Currently, the pathogenesis of ICI-associated neurotoxicities is not established, and clinical management and outcomes have only been derived from case reports/case series.